Rasagiline alone and in combination with riluzole
prolongs survival in an ALS mouse model
Waibel S, Reuter A, Malessa S, Blaugrund E, Ludolph AC.
Department of Neurology, University of Ulm,
Oberer Eselsberg 45, 89081, Ulm, Germany.
J Neurol. 2004 Sep;251(9):1080-4.
ABSTRACTRasagiline is an antiapoptotic compound with neuroprotective potential. We examined its neuroprotective effect alone and in combination with the putative glutamate release blocker riluzole in the G93A model of familial amyotrophic lateral sclerosis (fALS). Endpoints of experimental treatment were survival and motor activity. The drug had a significant dose-dependent therapeutic effect on both preclinical and clinical motor function and survival of the animals. We also found that the combination of rasagiline with riluzole is safe and increases survival by about 20 % in a dosedependent manner. Therefore, we conclude that the combination of rasagiline and riluzole is a promising clinical combination for the improvement of current neuroprotective treatment strategies of ALS.
and further reading
Dopaminergic cell death
Parkinson's disease: resources
Parkinson's disease and sleep disorders
Rasagiline/ anti-apoptotic bcl-2 gene family
Dual AChE and MAO inhibitors and Alzheimer's
Rasagiline v selegiline: neuronal survival effects
Rasagiline (Agilect) in early Parkinson's disease
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World
The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family